• Drug: Entyvio (vedolizumab)
  • Manufacturer: Takeda

  • Route of Administration: Intravenous, Subcutaneous

  • Site of Care: Outpatient

  • Approved Indication:

    • treatment of moderately to severely active ulcerative colitis
    • treatment of moderately to severely active Crohn’s disease
  • Disease: Crohn’s disease, ulcerative colitis
  • Therapeutic Area: Gastroenterology
  • Enrollment Form Link: www.entyvio.com/patient-support
  • Phone Number: 1-855-ENTYVIO (1-855-368-9846)
  • Fax Number: 1-877-488-6814

  • Product Website: entyvio.com